Q BioMed
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Q BioMed generated cash of $1,941,404, which is more than the previous year. Cash used in financing activities reached the amount of $907,761 last year. Net change in cash is therefore -$294,036.
Cash Flow
| 2013 | 0 | 0 | 25K |
|---|---|---|---|
| 2014 | -37.35K | 0 | 25K |
| 2015 | -91.39K | 0 | 210.15K |
| 2016 | -1.54M | 0 | 2.88M |
| 2017 | -5.58M | 0 | 4.94M |
| 2018 | -6.45M | -500K | 8.81M |
| 2019 | -4.10M | 0 | 1.59M |
| 2020 | -6.23M | 0 | 6.23M |
| 2021 | -4.30M | 0 | 4.46M |
| 2022 | 1.94M | -3.14M | 907.76K |
QBIO Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 344.00K | 177.14K | 172.63K | 2.68M | 824.78K | 1.46M | 131.40K | 12.64K | 25K | 0 |
Operating activities | ||||||||||
Net income | -2.05M | -8.24M | -13.49M | -10.27M | -9.27M | -14.54M | -7.17M | -1.08M | -38.05K | -500 |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 50K | 50K | 50K | 50K | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 903.82K | 2.33M | 6.57M | 2.49M | 0 | 6.39K | 4.13K | 225 | 0 | 0 |
| Deferred income tax benefit | 903.82K | 2.33M | 6.57M | 2.49M | 0 | 6.39K | 4.13K | 225 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 68.56K | -80.09K | -89.67K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | -80.09K | -324.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.47M | 838.69K | 569.19K | 1.40M | -71.30K | -34.39K | 439.13K | 90.11K | 699 | 500 |
Cash generated by operating activities | 1.94M | -4.30M | -6.23M | -4.10M | -6.45M | -5.58M | -1.54M | -91.39K | -37.35K | 0 |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | -500K | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3.14M | 0 | 0 | 0 | -500K | 0 | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 100.03K | 1.01M | 322.95K | 623.25K | 4.94M | 2.37M | 237.57K | 198.14K | 25K | 25K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.96M | 0 | 0 | 0 | 160.5K | 548K | 0 | 0 |
Repayments of term debt | 652.73K | -3.45M | -1.96M | 970K | -3.86M | 2.5M | -2.64M | 210.15K | 0 | 0 |
Cash used in financing activities | 907.76K | 4.46M | 6.23M | 1.59M | 8.81M | 4.94M | 2.88M | 210.15K | 25K | 25K |
Net Change In Cash | -294.03K | 166.86K | 4.50K | -2.51M | 1.85M | -643.94K | 1.33M | 118.75K | -12.35K | 25K |
Cash at end of period | 49.97K | 344.00K | 177.14K | 172.63K | 2.68M | 824.78K | 1.46M | 131.40K | 12.64K | 25K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |